| CRSPR Stock Could Be Ready to Deliver on Its Massive Promise |
Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it's here today and CRSPR Therapeutics AG NASDAQ: CRSP is leading the way. |
marketbeat.com |
2025-05-16 11:15:05 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It |
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
zacks.com |
2025-05-13 14:00:59 |
Czytaj oryginał (ang.) |
| 2 Biotech Stocks That Are Screaming Buys in May |
It's very tempting to pile into the stocks with the strongest positive momentum of the moment -- they've proven themselves and could continue along this path. But in many cases, you could set yourself up for a bigger win if you look to quality companies that have seen their stocks stumble in recent times. |
fool.com |
2025-05-13 11:10:00 |
Czytaj oryginał (ang.) |
| Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? |
Our genetics are like nature's roadmap. Our DNA dictates what color eyes we have, how tall we become, and our physical abilities. |
fool.com |
2025-05-12 10:18:00 |
Czytaj oryginał (ang.) |
| 3 Monster Stocks to Hold for the Next 10 Years |
The best investments are often stocks of companies offering goods and services that are perpetually in demand. Think entertainment, healthcare, or more recently, some consumer technologies. |
fool.com |
2025-05-10 09:12:00 |
Czytaj oryginał (ang.) |
| Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines |
CRSP's main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It's a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy's rollout has been slow due to its high cost, specialized centers, and lengthy required preconditioning. Still, CRSP will eventually receive 40% of Casgevy's profits through its partnership with VRTX. |
seekingalpha.com |
2025-05-09 11:14:50 |
Czytaj oryginał (ang.) |
| Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought |
Growth stocks have been rallying in recent weeks, and that's usually great news for Cathie Wood. The founder, CEO, and stock-picking ace of the Ark Invest family of exchange-traded funds (ETFs) has momentum on her side. |
fool.com |
2025-05-08 15:22:00 |
Czytaj oryginał (ang.) |
| Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet |
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? |
zacks.com |
2025-05-08 14:37:07 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade) |
CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active but no recognized revenue yet, reflecting a complex administration process and gradual gene therapy adoption. Regulatory uncertainties under Dr. Vinay Prasad's FDA leadership could delay approvals, impacting CRISPR's gene and cell therapy timelines. |
seekingalpha.com |
2025-05-08 12:36:44 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst |
CRISPR Therapeutics AG CRSP reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. |
benzinga.com |
2025-05-07 18:17:45 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks |
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates. |
zacks.com |
2025-05-07 12:40:40 |
Czytaj oryginał (ang.) |
| These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results |
CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. |
benzinga.com |
2025-05-07 12:39:41 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates |
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago. |
zacks.com |
2025-05-06 22:25:34 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 |
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- |
globenewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics (CRSP) Short Sellers Have A Lot Riding on Earnings |
Shares of CRISPR Therapeutics (NASDAQ:CRSP) can't seem to catch a break, now down close to 8% year to date and more than 80% from now-distant 2021 all-time highs. |
247wallst.com |
2025-05-05 11:18:53 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts |
Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better positioned to navigate near-term challenges with a strong cash reserve and upcoming product launches, justifying an upgrade to 'Strong Buy.' NTLA, despite promising product candidates, faces higher risks and requires significant cost reductions to extend its cash runway, maintaining a "Buy" rating for high-risk investors. |
seekingalpha.com |
2025-05-05 08:44:56 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts |
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.25, moving +1.38% from the previous trading session. |
zacks.com |
2025-05-02 22:50:32 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know |
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-05-02 14:00:55 |
Czytaj oryginał (ang.) |
| 2 Beaten-Down Stocks With Incredible Upside Potential |
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors. |
fool.com |
2025-04-30 09:14:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts |
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day. |
zacks.com |
2025-04-24 22:55:48 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference |
ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. |
globenewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It |
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-02-20 12:00:48 |
Czytaj oryginał (ang.) |
| CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell? |
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm. |
zacks.com |
2025-02-18 12:16:14 |
Czytaj oryginał (ang.) |
| Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future |
Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securities. Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes. The company is focused on easing pre-conditioning regimes and developing allogeneic and in-vivo therapies, which could exponentially increase the addressable market and drive future revenue growth. |
seekingalpha.com |
2025-02-13 13:06:18 |
Czytaj oryginał (ang.) |
| Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday |
On Hump Day, investors piled into CRISPR Therapeutics (CRSP 9.29%) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcare company's latest quarterly earnings report, which was published after market hours Tuesday. |
fool.com |
2025-02-12 20:37:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates |
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well. |
zacks.com |
2025-02-12 12:36:32 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates |
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago. |
zacks.com |
2025-02-11 20:12:09 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
-2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 patients have had cells collected across all regions as of the end of 2024- -Clinical trials ongoing for next-generation CAR T product candidates, CTX112™ and CTX131™, targeting CD19 and CD70 across multiple indications; updates for CTX112 in oncology and autoimmune diseases are expected in mid-2025 with CTX131 updates expected in 2025- -CRISPR Therapeutics and Nkure Therapeutics Private Limited establish global strategic partnership to co-develop and co-commercialize CTX112 in India- -Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and LPA, respectively; updates expected in the first half of 2025- -Strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of December 31, 2024- ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024. "With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics is poised to make meaningful strides in transforming the landscape of medicine. |
globenewswire.com |
2025-02-11 18:01:00 |
Czytaj oryginał (ang.) |
| Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move |
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities. |
fool.com |
2025-02-10 08:15:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy? |
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product. |
zacks.com |
2025-02-07 12:16:22 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript) |
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. |
seekingalpha.com |
2025-02-05 18:16:33 |
Czytaj oryginał (ang.) |
| Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade) |
Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized treatment centers for Casgevy and advancing multiple drug candidates in hemoglobinopathies, CAR-T, and in vivo programs. |
seekingalpha.com |
2025-02-05 17:48:26 |
Czytaj oryginał (ang.) |
| Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today |
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day. |
zacks.com |
2025-02-04 21:05:48 |
Czytaj oryginał (ang.) |
| Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates? |
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings. |
zacks.com |
2025-02-03 10:45:30 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors |
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. |
zacks.com |
2025-01-29 20:57:27 |
Czytaj oryginał (ang.) |
| DeepSeek AI picks 2 stocks to buy and hold forever |
Chinese-based generative artificial intelligence (AI) start-up DeepSeek is dominating conversations in technology and stock markets due to its performance, reportedly rivaling dominant players such as OpenAI's ChatGPT. |
finbold.com |
2025-01-27 12:44:31 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know |
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $43.42, moving -1.83% from the previous trading session. |
zacks.com |
2025-01-24 21:06:24 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last? |
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-01-23 11:31:18 |
Czytaj oryginał (ang.) |
| My Top 5 Stocks to Buy in Early 2025 |
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in 2025 and over the long term. The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game-changing technologies to big pharma or medical device players selling blockbuster drugs and paying out dividends to investors. |
fool.com |
2025-01-23 06:15:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell? |
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales. |
zacks.com |
2025-01-17 11:52:33 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know |
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day. |
zacks.com |
2024-12-31 20:55:35 |
Czytaj oryginał (ang.) |
| Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025 |
Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024. Despite a slow roll-out, Casgevy's increasing patient demand, reimbursement agreements, and positive long-term efficacy data support a bright revenue outlook and potential profitability by 2028. Crispr's robust pipeline, including CTX310 and CTX320 for cardiovascular diseases, holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects. |
seekingalpha.com |
2024-12-29 14:56:01 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors |
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $41.07, representing a +0.32% change from its previous close. |
zacks.com |
2024-12-26 21:06:26 |
Czytaj oryginał (ang.) |
| Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term |
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL. |
zacks.com |
2024-12-23 10:50:17 |
Czytaj oryginał (ang.) |
| This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? |
What's going on with CRISPR Therapeutics (CRSP 0.83%)? The company's shares have been southbound for the better part of three years. |
fool.com |
2024-12-22 14:25:00 |
Czytaj oryginał (ang.) |
| 1 big new Green Flag for CRISPR Therapeutics' Stock |
CRISPR Therapeutics (CRSP -1.64%) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth. |
fool.com |
2024-12-20 11:30:00 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 |
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025. |
zacks.com |
2024-12-17 12:01:04 |
Czytaj oryginał (ang.) |
| 2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? |
Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025. |
fool.com |
2024-12-17 07:29:00 |
Czytaj oryginał (ang.) |
| 3 Things You Need to Know if You Buy CRISPR Therapeutics Today |
CRISPR Therapeutics (CRSP -3.57%) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases. |
fool.com |
2024-12-14 11:45:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting |
-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- |
globenewswire.com |
2024-12-09 14:00:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock? |
CRISPR Therapeutics (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-09 08:47:47 |
Czytaj oryginał (ang.) |
| 2 Biotech Stocks to Buy Hand Over Fist in December |
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. |
fool.com |
2024-12-07 10:45:00 |
Czytaj oryginał (ang.) |
| Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report? |
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-05 14:36:03 |
Czytaj oryginał (ang.) |
| 3 of the Best Growth Stocks You Can Buy for Less than $100 |
It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher price is one of the criteria. |
fool.com |
2024-12-05 07:27:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 58.3% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-12-02 20:45:30 |
Czytaj oryginał (ang.) |
| Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65% |
Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum. |
fool.com |
2024-11-30 06:35:00 |
Czytaj oryginał (ang.) |
| Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? |
On Nov. 21, shares of CRISPR Therapeutics (CRSP 3.44%) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies. |
fool.com |
2024-11-24 07:47:00 |
Czytaj oryginał (ang.) |
| 3 Monster Stocks in the Making |
3 Monster Stocks in the Making |
fool.com |
2024-11-23 08:30:00 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript) |
CRISPR Therapeutics AG (NASDAQ:CRSP ) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Hi, everyone. My name is Maury Raycroft, I'm one of the biotech analysts at Jeffreys. |
seekingalpha.com |
2024-11-20 23:28:53 |
Czytaj oryginał (ang.) |
| CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? |
The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts. |
zacks.com |
2024-11-20 12:26:46 |
Czytaj oryginał (ang.) |